Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats
Molecular and Cellular Endocrinology · 2024
DOI: 10.1016/j.mce.2024.112374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024. Verfasst von Camila Lüdke Rossetti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Department of Internal Medicine, Division…. Hauptthemen laut MEDLINE: Liraglutide, Ovariectomy, Rats, Wistar. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Estrogens exert beneficial metabolic effects by reducing food intake and enhancing energy expenditure through both central and peripheral mechanisms. The decrease of estrogen, as occurs in ovariectomy (OVX), leads to metabolic disturbances, such as increased body weight, adipose tissue mass, basal blood glucose, and impaired glucose tolerance. These effects can be reversed by reintroducing estrogen. GLP-1 and its receptor agonists, known for their antihyperglycemic properties, also exhibit anorexigenic effects. Besides that, research indicates that GLP-1 analogs can induce metabolic changes peripherally, such as increased fatty acid oxidation and inhibited lipogenesis. Given the shared metabolic actions of GLP-1 and estrogens, we explored whether liraglutide, a GLP-1 agonist, could mitigate the metabolic effects of estrogen deficiency. We tested this hypothesis using ovariectomized rats, a model that simulates menopausal estrogen deficiency, and treated them with either liraglutide or 17β-Estradiol benzoate for 21 days. Ovariectomy resulted in elevated DPP-IV activity in both plasma and inguinal white adipose tissue (iWAT). While estrogen replacement effectively countered the DPP-IV increase in both plasma and iWAT, liraglutide only prevented the rise in iWAT DPP-IV activity. Liraglutide prevented body weight and fat mass gain after ovariectomy to the same extent as estradiol treatment. This can be explained by the lower food intake and food efficiency caused by estradiol and liraglutide. However, liraglutide was associated with increased pro-inflammatory cytokines and inflammatory cells in white adipose tissue. Further research is crucial to fully understand the potential benefits and risks of using GLP-1 receptor agonists in the context of menopause.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine,…
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
- Laboratorio de Fisiologia Endócrina, Instituto de Biologia, Universidade Do Estado Do Rio de Janeiro, Rio de Janeiro, Brazil.
- Laboratório de Pesquisa Clínica e Experimental em Biologia Vascular (BioVasc), Universidade Do Estado Do Rio de Janeiro, Rio de Janeiro, Brazil.
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Programa de Pós-Graduação em Ciências Cirúrgicas, Faculdade de Medicina, Universidade Federal Do Rio de Janeiro…
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: rodrigof@biof.ufrj.br.
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Rossetti, C. L., Andrade, I. S., Fonte Boa, L. F., Neves, M. B., Fassarella, L. B., Bertasso, I. M., Souza, M. D. G. C., Bouskela, E., Lisboa, P. C., Takyia, C. M., Trevenzoli, I. H., Fortunato, R. S., & Carvalho, D. P. (2024). Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112374
Vancouver
Rossetti CL, Andrade IS, Fonte Boa LF, Neves MB, Fassarella LB, Bertasso IM, et al. Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats. Molecular and Cellular Endocrinology. 2024. doi:10.1016/j.mce.2024.112374
BibTeX
@article{Rossetti2024,
author = {Rossetti, Camila Lüdke and Andrade, Iris Soares and Fonte Boa, Luiz Fernando and Neves, Marcelo Barbosa and Fassarella, Larissa Brito and Bertasso, Iala Milene and Souza, Maria das Graças Coelho de and Bouskela, Eliete and Lisboa, Patrícia Cristina and Takyia, Christina Maeda and Trevenzoli, Isis Hara and Fortunato, Rodrigo Soares and Carvalho, Denise Pires de},
title = {Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
doi = {10.1016/j.mce.2024.112374}
}
EUVIMED